Citadel Advisors
URGN icon

Citadel Advisors’s UroGen Pharma URGN Stock Holding History

Citadel Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Buy
50,700
+35,400
+231% +$959K ﹤0.01% 6717
2026
Q1 		$275K Sell
15,300
-40,600
-73% -$814K ﹤0.01% 10668
2025
Q4 		$1.31M Sell
55,900
-29,900
-35% -$649K ﹤0.01% 6816
2025
Q3 		$1.71M Sell
85,800
-89,000
-51% -$1.6M ﹤0.01% 6393
2025
Q2 		$2.39M Buy
174,800
+103,600
+146% +$994K ﹤0.01% 5383
2025
Q1 		$787K Buy
71,200
+13,500
+23% +$144K ﹤0.01% 7489
2024
Q4 		$615K Buy
57,700
+47,900
+489% +$573K ﹤0.01% 8096
2024
Q3 		$124K Sell
9,800
-15,200
-61% -$226K ﹤0.01% 10825
2024
Q2 		$420K Buy
25,000
+2,600
+12% +$37K ﹤0.01% 8419
2024
Q1 		$336K Buy
22,400
+1,400
+7% +$22.9K ﹤0.01% 9223
2023
Q4 		$315K Sell
21,000
-6,500
-24% -$84.4K ﹤0.01% 9063
2023
Q3 		$385K Buy
27,500
+17,400
+172% +$279K ﹤0.01% 8633
2023
Q2 		$105K Sell
10,100
-45,700
-82% -$504K ﹤0.01% 10868
2023
Q1 		$516K Sell
55,800
-39,000
-41% -$359K ﹤0.01% 8239
2022
Q4 		$841K Buy
94,800
+74,900
+376% +$709K ﹤0.01% 7149
2022
Q3 		$166K Buy
+19,900
New +$165K ﹤0.01% 10608
2021
Q4 		– Sell
-36,800
Closed -$619K – 14794
2021
Q3 		$619K Sell
36,800
-700
-2% -$11.1K ﹤0.01% 9357
2021
Q2 		$573K Buy
37,500
+11,200
+43% +$203K ﹤0.01% 9751
2021
Q1 		$512K Buy
+26,300
New +$558K ﹤0.01% 9628
2020
Q3 		– Sell
-23,900
Closed -$624K – 10767
2020
Q2 		$624K Sell
23,900
-86,700
-78% -$2.12M ﹤0.01% 6672
2020
Q1 		$1.97M Sell
110,600
-2,400
-2% -$64.8K ﹤0.01% 4166
2019
Q4 		$3.77M Buy
113,000
+96,300
+577% +$2.63M ﹤0.01% 3470
2019
Q3 		$398K Buy
+16,700
New +$546K ﹤0.01% 7145

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Citadel Advisors's URGN Position: Q2 2026 in Review

Citadel Advisors reduced its UroGen Pharma (URGN) stake by 95% in Q2 2026, selling an estimated $6.91M and leaving 12,985 shares worth $478K. The position accounts for ﹤0.01% of the portfolio, ranked #9965.

Citadel Advisors first reported a position in URGN in Q1 2018 and has held it in 31 quarters since. The position peaked at $17.7M in Q3 2018. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Citadel Advisors held 12,985 shares of UroGen Pharma worth $478K as of Q2 2026.
  • Citadel Advisors sold 255,011 UroGen Pharma shares in Q2 2026, an estimated $6.91M.
  • UroGen Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9965 holding.
  • Citadel Advisors first reported a position in UroGen Pharma in Q1 2018 and has held it in 31 quarters since.
  • Citadel Advisors's UroGen Pharma position peaked at $17.7M in Q3 2018.
  • 190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.